Apogee Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Apogee Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($65.02M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($66.10M) | Aug 11, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($66.10M) | Nov 10, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($55.34M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($55.34M) | May 12, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($55.34M) | Nov 10, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($49.02M) | Nov 10, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($33.82M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($33.82M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($32.09M) | May 12, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($32.09M) | Aug 11, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($32.09M) | Nov 10, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($20.84M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($18.89M) | Aug 12, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($18.89M) | Nov 12, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($12.53M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.53M) | May 13, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($12.53M) | Nov 12, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($19.66M) | Nov 13, 2023 |
| Q3 | 2023 | Jun 30, 2022 | ($1.82M) | Nov 13, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($71.28M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($73.17M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($63.10M) | May 12, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($58.69M) | Nov 10, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($44.12M) | Aug 11, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($38.18M) | May 12, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($24.31M) | Nov 12, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($18.89M) | Aug 12, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($12.66M) | May 13, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($10.51M) | Nov 13, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($1.82M) | Aug 28, 2023 |